Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, announced the clinching of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads.

Precirix’s platform brings together several unique features and facilitates the development of radio-labelled single-domain antibodies (sdAbs) for multiple targets, in combination with different isotopes and applicability in various settings. The company's lead product candidate, CAM-H2, is currently in a Phase I/II study for the treatment of HER2-positive metastatic breast and gastric cancer. The study allows for the inclusion of patients with brain metastases, a population in urgent need of effective therapies. Initial imaging data provides confidence in the potential of CAM-H2 to address the unmet medical need in this population.

The proceeds of this financing round will fund the development and expansion of Precirix’s pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the clinic. Precirix will also focus on further strengthening the platform, using its potential to generate new product candidates, linkers, and CMC processes.

To read more please visit:

Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals

Source: Precirix